Loading...
Gene Editing Royalties And Slow Adoption Will Pressure Results Yet Support Long Term Upside
AN
AnalystLowTarget
Not Invested
Community Contributor
Published
11 Jan 26
Views
10
11 Jan
US$1.07
AnalystLowTarget's Fair Value
US$5.00
78.6% undervalued intrinsic discount1Y
-51.4%7D
4.9%1Y
-51.4%7D
4.9%You can edit this narrative until Jan 12 2:05 AM. Then, changes will post as Updates.
Author's Valuation
US$578.6% undervalued intrinsic discount
AnalystLowTarget Fair Value